Sanofi shares are trading lower. Royalty Pharma acquired a royalty interest in the company's Frexalimab.
Portfolio Pulse from Benzinga Newsdesk
Sanofi's shares are trading lower following the announcement that Royalty Pharma has acquired a royalty interest in Sanofi's Frexalimab.
May 09, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sanofi's shares are trading lower due to Royalty Pharma's acquisition of a royalty interest in Frexalimab.
The acquisition of a royalty interest in Frexalimab by Royalty Pharma is likely to have a negative short-term impact on Sanofi's stock price. This news may raise concerns among investors regarding future revenue potential from Frexalimab, leading to a decrease in stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90